Feb 8- Breast implant maker Sientra Inc said it will resume selling all of its medical devices in the U.S. market from March 1, four months after it suspended sales of its breast implant devices to ensure technical compliance. The company had put a hold on sales of its implants in October, citing some technical compliance issues at Brazilian contract manufacturer...» Read More
Jim Cramer believes this company is about to create immense value with the stroke of a pen.
When architect Michael Graves realized he would spend the rest of his life in a wheelchair, he set out to improve medical design. This week Stryker unveils his wheelchair.
Bristol-Myers Squibb and Merck stocks climbed higher Monday as analysts said billions stood to be made from treatment breakthroughs.
Americans accustomed to immediate access to the newest technology may be shocked to find that is not the case when it comes to devices that treat ailing hearts.
Cramer’s convinced the best way to for this health care company to maximize shareholder value is to break up.
The rise of "superbugs," and pressure from the government and insurers, is driving hospitals to try all sorts of new approaches to stop their spread.
Most robotic surgery takes place without a hitch, but a growing number of complaints and lawsuits allege complications and even deaths from Intuitive Surgical's da Vinci device.
If the critics of robotic surgery are right—that safety is an issue—how is that it was performed on 450,000 people last year? The answer may lie in one word: Marketing.
The number of complications from robot-assisted surgery using Intuitive Surgical's da Vinci robot are underreported, allege critics of the procedure, fanning the controversy around the company's pioneering product.
Intuitive Surgical's da Vinci robot was once hailed as a revolution in the operating room, but as more reports of complications have come to light, the da Vinci debate is heating up.
In recent years, as the surgical robot's popularity has grown, so have questions and concerns about its safety, training and the aggressiveness of its marketing.
A sharp and surprisingly persistent slowdown in the growth of health care costs is helping to narrow the federal deficit, leaving budget experts trying to figure out whether the trend will last.
An internal analysis conducted by Johnson & Johnson in 2011 estimated that the all-metal device would fail within five years in nearly 40 percent of patients who received it, newly disclosed court records show.
DaVita could be a beneficiary among health care stocks from changes in the U.S. health care market, an analyst said Wednesday.
It was a complicated case, in part because the reform legislation itself was seriously flawed. The law’s drafters could have proposed a simpler and more efficient system, the New York Times reports.
While some people are frustrated about the long wait times for doctors appointments, some believe doctors are doing their jobs.
American spends more on health care than any other country. Do you know where it goes?
Over the last 20 years, Americans have witnessed unprecedented advances in care of hospitalized patients. Improved diagnostic procedures, quantum leaps in medical technology, enhanced treatments and a public now familiar with the concept of preventative medical care all mean that healthcare – especially in the hospital – has changed to meet the health care needs of today’s patients.
With stocks shrugging off the wall of worry in the first quarter, the second quarter could prove to be a less rewarding time for those long equity markets as central banks begin to tighten policy via rate hikes or withdrawing extraordinary measures.
The "Mad Money" host shares a few interesting spec plays in the health care space.